Clinical behavior and treatment outcome of primary nasal diffuse large B‐cell lymphoma

Abstract

BACKGROUND: Nasal diffuse large B-cell lymphoma (DLBCL) is rare. The objective of this study was to evaluate the clinical features and treatment outcomes of patients with nasal DLBCL. METHODS: Twenty-five patients were included in the study. All patients received combination chemotherapy with or without radiotherapy. RESULTS: Patients with nasal DLBCL usually were older and were predominantly men with early stage disease, low frequency of B symptoms and elevated lactate dehydrogenase (LDH), good performance status, and a low-risk international prognostic index (IPI) score. The overall response rate after initial treatment was 76%, the 3-year overall survival (OS) rate for the whole group was 44%, and the median OS was 35 months. Performance status and IPI were significant prognostic factors for OS. For patients with IPI scores of 0 or 1, the 3-year OS rate was 54%, and the median OS was 52 months compared with 17% and 11 months, respectively, for patients with IPI scores of 2 or 3 (P ¼ .033). The prognosis for patients who achieved a complete response (CR) was significantly better than that for patients who did not achieve a CR. Extranodal spread was the primary pattern of failure. CONCLUSIONS: The current results indicated that primary nasal DLBCL appears to have distinct clinical features; its poor outcome and propensity for extranodal failure illustrate the need for innovative therapies. Cancer 2012;118:1593-

Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma

“…Nevertheless, the true prognosis of patients with SN-DLBCL remains controversial, as does how to achieve the best treatment outcomes after the introduction of R, due to the rarity of the disease and the heterogeneity of current treatment options regarding the incorporation of IFRT. Lu et al reported that the 3-year OS rate in 25 patients with nasal DLBCL was only 44%, although these patients predominantly had early-stage disease, low-risk IPI and high response rates [15]. However, other studies have suggested a more favorable prognosis for patients with…”

Primary Diffuse Large B-Cell Non-Hodgkin Lymphoma of the Paranasal Sinuses: Case Report

“…Monoklonal anti CD-20 antikoru rituksimabın kullanımıyla sağkalım oranları artmıştır. 7 Italiano ve ark. 80 yaş üzeri hastalarda düşük doz CHOP kemoterapi protokolüne ek olarak verdikleri rituksimab tedavisi sonucunda 2 yıl üzeri sağ kalımı %60 olarak göstermişlerdir.…”

Linfoma en fosa nasal encontrado durante una dacriocistorrinostomía

“…A histologia maiormente encontrada é de carácter não epitelial primário. Muitos dos pacientes em séries revisadas têm tido diagnóstico 1 …”

“…La afección de las fosas nasales está descrita entre el 1.5% -5%, se encuentra mayormente en pacientes entre la octava y novena décadas de la vida, y en más proporción en pacientes de raza asiática 1,2 . Si bien, en esta raza son más comunes los linfomas en el área nasal, en poblaciones occidentales también es descrita, con una variación histológica respecto a su presentación y el linfoma no Hodgkin con población de células B es el más frecuente en poblaciones occidentales, mientras en Perú y Asia se describe una prevalencia mayor de linfomas no Hodgkin con células T 3,4 .…”